Evidence map›Paper›PMID 24699093›Full record

ArticleAJNR. American journal of neuroradiology2014

Effects of gadolinium contrast agent administration on automatic brain tissue classification of patients with multiple sclerosis.

J B M Warntjes, A Tisell, A-M Landtblom, P Lundberg

Abstract readControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Article in AJNR. American journal of neuroradiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. The Effect of Gadolinium on Synthetic Magnetic Resonance Quantitative Imaging.Journal of neuroimaging : official journal of the American Society of Neuroimaging
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

J B M WarntjesFrom the Center for Medical Image Science and Visualization, (J.B.M.W., A.T., P.L.)Clinical Physiology (J.B.M.W.)Departments of Clinical Physiology (J.B.M.W.) marcel.warntjes@cmiv.liu.se.
A TisellFrom the Center for Medical Image Science and Visualization, (J.B.M.W., A.T., P.L.)Radiation Physics (A.T.), Department of Medical and Health Sciences, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
A-M LandtblomClinical Neuroscience (A.-M.L.)Neurology, Department of Clinical and Experimental Medicine (A.-M.L.), Linköping University, Linköping, Sweden.
P LundbergFrom the Center for Medical Image Science and Visualization, (J.B.M.W., A.T., P.L.)Radiation Physics (P.L.), Department of Medical and Health Sciences, Linköping University, Linköping, SwedenRadiation Physics (P.L.), UHL, County Council of Östergötland, Linköping, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe administration of gadolinium contrast agent is a common part of MR imaging examinations in patients with MS. The presence of gadolinium may affect the outcome of automated tissue classification. The purpose of this study was to investigate the effects of the presence of gadolinium on the automatic segmentation in patients with MS by using the synthetic tissue-mapping method. MATERIALS AND

methodsA cohort of 20 patients with clinically definite multiple sclerosis were recruited, and the T1 and T2 relaxation times and proton density were simultaneously quantified before and after the administration of gadolinium. Synthetic tissue-mapping was used to measure white matter, gray matter, CSF, brain parenchymal, and intracranial volumes. For comparison, 20 matched controls were measured twice, without gadolinium.

resultsNo differences were observed for the control group between the 2 measurements. For the MS group, significant changes were observed pre- and post-gadolinium in intracranial volume (-13 mL, P < .005) and cerebrospinal fluid volume (-16 mL, P < .005) and the remaining, unclassified non-WM/GM/CSF tissue volume within the intracranial volume (+8 mL, P < .05). The changes in the patient group were much smaller than the differences, compared with the controls, which were -129 mL for WM volume, -22 mL for GM volume, +91 mL for CSF volume, 24 mL for the remaining, unclassified non-WM/GM/CSF tissue volume within the intracranial volume, and -126 mL for brain parenchymal volume. No significant differences were observed for linear regression values against age and Expanded Disability Status Scale.

conclusionsThe administration of gadolinium contrast agent had a significant effect on automatic brain-tissue classification in patients with MS by using synthetic tissue-mapping. The observed differences, however, were much smaller than the group differences between MS and controls.

Indexed as

Gadolinium DTPABrainContrast MediaFemaleGray MatterHumansImage EnhancementMagnetic Resonance ImagingMaleMiddle AgedMultiple SclerosisPattern Recognition, AutomatedReproducibility of ResultsSensitivity and SpecificityWhite MatterContrast MediaGadolinium DTPA

Identifiers

PMID24699093
PMCPMC7966571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.